Chronic Granulomatous Disease Market Research Report Information By Diagnosis (Neutrophil Function Tests, Genetic Testing, Others), by Treatment (Infection Management, Interferon-gamma, Stem Cell Transplantation), by End-User (Hospitals, Others) - Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chronic Granulomatous Disease Market, by Type

6.1 Introduction

6.2 X-Linked Chronic Granulomatous Disease

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Autosomal Recessive Chronic Granulomatous Disease

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Chronic Granulomatous Disease Market, by Diagnosis

7.1 Introduction

7.2 Neutrophil Function Test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Genetic Testing

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Prenatal Testing

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Others

Chapter 8. Global Chronic Granulomatous Disease Market, by Treatment

8.1 Introduction

8.2 Infection Management

8.2.1 Trimethoprim

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2 Sulfamethoxazole

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.3 Itraconazole

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.4 Others

8.3 Interferon-gamma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Stem Cell Transplantation

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Others

Chapter 9. Global Chronic Granulomatous Disease Market, by End-User

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Clinical Laboratory

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Others

Chapter 10. Global Chronic Granulomatous Disease Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Pfizer, Inc.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 InterMune, Inc.

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Novartis AG

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Lonza Group

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 GlaxoSmithKline Plc

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Eli Lily and Company

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Janssen Pharmaceuticals

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Merck KGaA

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Osiris Therapeutics, Inc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 JCR Pharmaceuticals Co., Ltd

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Maxcyte, Inc.

12.11.1 Overview

12.11.2 Product Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Horizon Pharma Plc

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Chronic Granulomatous Disease Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Chronic Granulomatous Disease Market Synopsis, 2020–2027

Table 2 Global Chronic Granulomatous Disease Market Estimates and Forecast, 2020–2027

(USD Million)

Table 3 Global Chronic Granulomatous Disease Market, by Region, 2020–2027 (USD Million)

Table 4 Global Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

Table 5 Global Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

Table 6 Global Chronic Granulomatous Disease Market, by Treatment, 2020–2027(USD Million)

Table 7 Global Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD Million)

Table 8 North America: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD

Million)

Table 9 North America: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD

Million)

Table 10 North America: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 11 North America: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

Million)

Table 12 US: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

Table 13 US: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

Table 14 US: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD Million)

Table 15 US: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD Million)

Table 16 Canada: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

Table 17 Canada: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

Table 18 Canada: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 19 Canada: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

Million)

Table 20 South America: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD

Million)

Table 21 South America: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD

Million)

Table 22 South America: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

(USD Million)

Table 23 South America: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

Million)

Table 24 Europe: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

Table 25 Europe: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

Table 26 Europe: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 27 Europe: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD Million)

Table 28 Western Europe: Chronic Granulomatous Disease Market, by Type, 2020–2027

(USD Million)

Table 30 Western Europe: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 31 Western Europe: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

(USD Million)

Table 32 Western Europe: Chronic Granulomatous Disease Market, by End-User, 2020–2027

(USD Million)

Table 33 Eastern Europe: Chronic Granulomatous Disease Market, by Type, 2020–2027

(USD Million)

Table 34 Eastern Europe: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 35 Eastern Europe: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

(USD Million)

Table 36 Eastern Europe: Chronic Granulomatous Disease Market, by End-User, 2020–2027

(USD Million)

Table 37 Asia-Pacific: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD

Million)

Table 38 Asia-Pacific: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD

Million)

Table 39 Asia-Pacific: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

Million)

Table 40 Asia-Pacific: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

Million)

Table 41 Middle East & Africa: Chronic Granulomatous Disease Market, by Type, 2020–2027

(USD Million)

Table 42 Middle East & Africa: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027

(USD Million)

Table 43 Middle East & Africa: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

(USD Million)

Table 44 Middle East & Africa: Chronic Granulomatous Disease Market, by End-User, 2020–2027

(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Chronic Granulomatous Disease Market

Figure 3 Segmentation Market Dynamics for Global Chronic Granulomatous Disease Market

Figure 4 Global Chronic Granulomatous Disease Market Share, by Type, 2020

Figure 5 Global Chronic Granulomatous Disease Market Share, by Diagnosis, 2020

Figure 6 Global Chronic Granulomatous Disease Market Share, by Treatment, 2020

Figure 7 Global Chronic Granulomatous Disease Market Share, by End-User, 2020

Figure 8 Global Chronic Granulomatous Disease Market Share, by Region, 2020

Figure 9 North America: Chronic Granulomatous Disease Market Share, by Country, 2020

Figure 10 Europe: Chronic Granulomatous Disease Market Share, by Country, 2020

Figure 11 Asia-Pacific: Chronic Granulomatous Disease Market Share, by Country, 2020

Figure 12 Middle East & Africa: Chronic Granulomatous Disease Market Share, by Country, 2020

Figure 13 Global Chronic Granulomatous Disease Market: Company Share Analysis, 2020 (%)

Figure 14 Pfizer, Inc.: Key Financials

Figure 15 Pfizer, Inc.: Segmental Revenue

Figure 16 Pfizer, Inc.: Geographical Revenue

Figure 17 InterMune, Inc.: Key Financials

Figure 18 InterMune, Inc.: Segmental Revenue

Figure 19 InterMune, Inc.: Geographical Revenue

Figure 20 Novartis AG: Key Financials

Figure 21 Novartis AG: Segmental Revenue

Figure 22 Novartis AG: Geographical Revenue

Figure 23 Lonza Group : Key Financials

Figure 24 Lonza Group: Segmental Revenue

Figure 25 Lonza Group : Geographical Revenue

Figure 26 GlaxoSmithKline Plc: Key Financials

Figure 27 GlaxoSmithKline Plc: Segmental Revenue

Figure 28 GlaxoSmithKline Plc. Geographical Revenue

Figure 29 Eli Lily and Company: Key Financials

Figure 30 Eli Lily and Company: Segmental Revenue

Figure 31 Eli Lily and Company: Geographical Revenue

Figure 32 Janssen Pharmaceuticals: Key Financials

Figure 33 Janssen Pharmaceuticals: Segmental Revenue

Figure 34 Janssen Pharmaceuticals: Geographical Revenue

Figure 35 Merck KGaA: Key Financials

Figure 36 Merck KGaA: Segmental Revenue

Figure 37 Merck KGaA: Geographical Revenue

Figure 38 Osiris Therapeutics, Inc.: Key Financials

Figure 39 Osiris Therapeutics, Inc.: Segmental Revenue

Figure 40 Osiris Therapeutics, Inc.: Geographical Revenue

Figure 41 JCR Pharmaceuticals Co., Ltd: Key Financials

Figure 42 JCR Pharmaceuticals Co., Ltd: Segmental Revenue

Figure 43 JCR Pharmaceuticals Co., Ltd: Geographical Revenue

Figure 44 Maxcyte, Inc.: Key Financials

Figure 45 Maxcyte, Inc.: Segmental Revenue

Figure 46 Maxcyte, Inc.: Geographical Revenue

Figure 47 Horizon Pharma Plc: Key Financials

Figure 48 Horizon Pharma Plc: Segmental Revenue

Figure 49 Horizon Pharma Plc: Geographical Revenue